logo-loader
viewMaxCyte Inc

Healthcheck on cell therapy group MaxCyte

MaxCyte Inc (LON:MXCT) updates investors on its cellular editing technology ahead of new results out tomorrow.
CEO Doug Doefler tells Proactive London why short/medium and long term goals for the company are bang on track as he looks forward to a  new generation of cell therapy techniques that MaxCyte intends to develop.
The company provides patented, high-performance cell-engineering platforms to bio-pharmaceutical partners engaged in drug discovery and development, bio-manufacturing and cell therapy, including gene editing and immuno-oncology.

Quick facts: MaxCyte Inc

Price: 110 GBX

AIM:MXCT
Market: AIM
Market Cap: £63.13 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18

2 min read